These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 18459108)

  • 1. Extramedullary progression of multiple myeloma under thalidomide therapy despite concomitant response of medullary disease.
    Candoni A; Simeone E; Fanin R
    Am J Hematol; 2008 Aug; 83(8):680-1. PubMed ID: 18459108
    [No Abstract]   [Full Text] [Related]  

  • 2. Extramedullary multiple myeloma escapes the effect of thalidomide.
    Rosiñol L; Cibeira MT; Bladé J; Esteve J; Aymerich M; Rozman M; Segarra M; Cid MC; Filella X; Montserrat E
    Haematologica; 2004 Jul; 89(7):832-6. PubMed ID: 15257935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unusual myeloma relapse after thalidomide therapy: the dark side of the moon?
    Balleari E; Bruzzone A
    Leuk Res; 2009 Sep; 33(9):1164-5. PubMed ID: 19446332
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of thalidomide in the treatment of multiple myeloma.
    Warzocha K; Kraj M; Pogłód R; Szpila T; Mendek-Czajkowska E; Chełstowska M; Tronina RH
    Acta Pol Pharm; 2008; 65(6):771-4. PubMed ID: 19172865
    [No Abstract]   [Full Text] [Related]  

  • 5. Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?
    Katodritou E; Gastari V; Verrou E; Hadjiaggelidou C; Varthaliti M; Georgiadou S; Laschos K; Xirou P; Yiannaki E; Constantinou N; Markala D; Zervas K
    Leuk Res; 2009 Aug; 33(8):1137-40. PubMed ID: 19250676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study.
    Offidani M; Corvatta L; Polloni C; Piersantelli MN; Gentili S; Galieni P; Visani G; Alesiani F; Catarini M; Brunori M; Samori A; Burattini M; Centurioni R; Ferranti M; Giuliodori L; Candela M; Mele A; Marconi M; Leoni P
    Br J Haematol; 2009 Mar; 144(5):653-9. PubMed ID: 19036082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients.
    Oliveira AM; Maria DA; Metzger M; Linardi C; Giorgi RR; Moura F; Martinez GA; Bydlowski SP; Novak EM
    Leuk Res; 2009 Jul; 33(7):970-3. PubMed ID: 18976811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects.
    Corso A; Zappasodi P; Barbarano L; Petrucci MT; Palumbo A; Caravita T; Mangiacavalli S; Cafro AM; Varettoni M; Gay F; Morra E; Lazzarino M
    Leuk Res; 2009 Sep; 33(9):e145-9. PubMed ID: 19375164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma.
    Avigdor A; Raanani P; Levi I; Hardan I; Ben-Bassat I
    Leuk Lymphoma; 2001 Aug; 42(4):683-7. PubMed ID: 11697498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma.
    Zemanova M; Scudla V; Adam Z; Gregora E; Pour L; Minarik J; Pavlicek P; Pika T; Bacovsky J
    Neoplasma; 2008; 55(4):345-9. PubMed ID: 18505347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of thalidomide in previously untreated patients with multiple myeloma.
    Musto P; D'Auria F; Pietrantuono G; Bringhen S; Morabito F; Di Raimondo F; Pozzi S; Sacchi S; Boccadoro M; Palumbo A; ;
    Expert Rev Anticancer Ther; 2008 Oct; 8(10):1569-80. PubMed ID: 18925849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
    Pönisch W; Rozanski M; Goldschmidt H; Hoffmann FA; Boldt T; Schwarzer A; Ritter U; Rohrberg R; Schwalbe E; Uhlig J; Zehrfeld T; Schirmer V; Haas A; Kreibich U; Niederwieser D;
    Br J Haematol; 2008 Oct; 143(2):191-200. PubMed ID: 18752593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible multiple myeloma dedifferentiation following thalidomide therapy: a report of four cases.
    Balleari E; Ghio R; Falcone A; Musto P
    Leuk Lymphoma; 2004 Apr; 45(4):735-8. PubMed ID: 15160948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term thalidomide therapy resulted in lack of mdr1 gene expression in a patient with primary resistant multiple myeloma.
    Hus M; Dmoszyńska A; Kocki J; Hus I; Jawniak D; Adamczyk-Cioch M; Grzasko N
    Leukemia; 2005 Aug; 19(8):1497-9. PubMed ID: 15920492
    [No Abstract]   [Full Text] [Related]  

  • 15. Thalidomide as anti-inflammatory therapy for multiple myeloma.
    Mehta P; Hussein M
    Leukemia; 2003 Nov; 17(11):2237-8; author reply 2238. PubMed ID: 12931217
    [No Abstract]   [Full Text] [Related]  

  • 16. Thalidomide induced impotence in male hematology patients: a common but ignored complication?
    Murphy PT; O'Donnell JR
    Haematologica; 2007 Oct; 92(10):1440. PubMed ID: 18024384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive myeloma after thalidomide therapy in a patient with immature phenotype of myeloma (plasma) cells.
    Okikawa Y; Sakai A; Takimoto Y; Noda M; Imagawa J; Katayama Y; Kuroda Y; Okita H; Fujimura K; Kimura A
    Int J Hematol; 2004 May; 79(4):364-8. PubMed ID: 15218967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
    J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma.
    Morris TC; Kettle PJ; Drake M; Jones FC; Hull DR; Boyd K; Morrison A; Clarke P; O'Reilly P; Quinn J
    Br J Haematol; 2008 Nov; 143(3):349-54. PubMed ID: 18759764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
    Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
    Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.